OrbiMed creates debt facility for pharmaceutical firm

OrbiMed Advisors led the completion of a $200 million debt facility for Harmony Biosciences, a firm that develops treatment options for people living with rare diseases.

The financing is slated to support the company’s commercialization of the narcolepsy treatment WAKIX (pitosilant) in the U.S. The U.S. Food and Drug Administration approved the product in August 2019, but Harmony is in the process of executing its commercial launch.

Harmony was launched in 2017 with an emphasis on treating rare and orphan diseases related to the central nervous system disorders.

As for . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.

Related Articles

Get started

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!